ES2167555T3 - Triazolonas como inhibidores de la sintesis de apolipoproteina-b. - Google Patents

Triazolonas como inhibidores de la sintesis de apolipoproteina-b.

Info

Publication number
ES2167555T3
ES2167555T3 ES96910968T ES96910968T ES2167555T3 ES 2167555 T3 ES2167555 T3 ES 2167555T3 ES 96910968 T ES96910968 T ES 96910968T ES 96910968 T ES96910968 T ES 96910968T ES 2167555 T3 ES2167555 T3 ES 2167555T3
Authority
ES
Spain
Prior art keywords
rent
replaced
phenyl
invention refers
apolipoproteina
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96910968T
Other languages
English (en)
Inventor
Jan Heeres
Leo Jacobus Jozef Backx
Paul August Clement Luyts
Chaffoy De Courcelles Didie De
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Application granted granted Critical
Publication of ES2167555T3 publication Critical patent/ES2167555T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Seasonings (AREA)
  • Saccharide Compounds (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A NUEVOS COMPUESTOS DE FORMULA (I), DONDE R1 ES ALQUILO C1-10 , CICLOALQUILO C37 O ALQUILO C1-6 SUSTITUIDO CON CICLOALQUILO C3-7 ; R2 ES HIDROGENO O ALQUILO C1-6 ; ALK REPRESENTA ALCANODIILO C1-3 ; -A- REPRESENTA UN RADICAL DIVALENTE DE FORMULA: (A) - CH = CH - N = CH -, (B) - N = CH - N = CH -, (C) CH = N - N = CH -, (D) - CH = CH - CH = N -; EN DICHOS RADICALES DIVALENTES, UN ATOMO DE HIDROGENO PUEDE SER REEMPLAZADO POR UN ALQUILO C1-6 ; Y AR ES UN FENILO NO SUSTITU IDO; FENILO SUSTITUIDO CON HASTA DOS SUSTITUYENTES SELECCIONADOS DE ENTRE HALO, ALQUILO C1-6 O ALQUILOXI C1-6 ; N AFTILO NO SUSTITUIDO O NAFTILO SUSTITUIDO CON HASTA DOS SUSTITUYENTES SELECCIONADOS DE ENTRE HALO, ALQUILO C1-6 O ALQUILOXI C1-6 ; SUS FORMAS ISOMEROS ESTEREOQUIMICOS, Y SUS SALES DE ADICION DE ACIDO FARMACEUTICAMENTE ACEPTABLES. LA PRESENTE INVENCION SE REFIERE ADEMAS A LAS COMPOSICIONES FARMACEUTICAS QUE INCLUYEN COMPUESTOS DE FORMULA (I), SU PREPARACION ASI COMO SU USO COMO MEDICAMENTOS EN EL TRATAMIENTO DE LA HIPERLIPIDEMIA.
ES96910968T 1995-04-20 1996-04-12 Triazolonas como inhibidores de la sintesis de apolipoproteina-b. Expired - Lifetime ES2167555T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP95201010 1995-04-20

Publications (1)

Publication Number Publication Date
ES2167555T3 true ES2167555T3 (es) 2002-05-16

Family

ID=8220206

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96910968T Expired - Lifetime ES2167555T3 (es) 1995-04-20 1996-04-12 Triazolonas como inhibidores de la sintesis de apolipoproteina-b.

Country Status (21)

Country Link
US (2) US5922718A (es)
EP (1) EP0871626B1 (es)
JP (1) JP3782455B2 (es)
KR (1) KR100413219B1 (es)
CN (1) CN1076727C (es)
AT (1) ATE208386T1 (es)
AU (1) AU699313B2 (es)
CA (1) CA2217632A1 (es)
CZ (1) CZ291737B6 (es)
DE (1) DE69616825T2 (es)
DK (1) DK0871626T3 (es)
ES (1) ES2167555T3 (es)
HU (1) HUP9801056A3 (es)
IL (1) IL117980A (es)
NO (1) NO312415B1 (es)
NZ (1) NZ305869A (es)
PL (1) PL183737B1 (es)
PT (1) PT871626E (es)
TW (1) TW457240B (es)
WO (1) WO1996033193A1 (es)
ZA (1) ZA963152B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004000284A1 (en) 2002-06-21 2003-12-31 Transform Pharmaceuticals, Inc. Pharmaceutical compositions with improved dissolution
CA2477923C (en) 2002-03-01 2021-02-23 University Of South Florida Multiple-component solid phases containing at least one active pharmaceutical ingredient
CA2525517C (en) * 2003-06-19 2016-05-31 Applied Research Systems Ars Holding N.V. Use of prion conversion modulating agents
US20080057057A1 (en) * 2004-03-18 2008-03-06 Applied Research Systems Ars Holding N.V. Anti-Lipid Rafts Antibodies
WO2005118577A1 (en) * 2004-04-22 2005-12-15 Transform Pharmaceuticals, Inc. Novel saperconazole crystalline forms and related processes, pharmaceutical compositions and methods
JP2008542255A (ja) * 2005-05-27 2008-11-27 ファイザー・プロダクツ・インク 肥満症の治療または体重減量の維持のためのカンナビノイド−１受容体アンタゴニストおよびミクロソームトリグリセリド輸送タンパク質阻害物質の併用
EP3626242B1 (en) 2013-06-07 2024-08-07 The Scripps Research Institute Itraconazole analogs as inhibitors of fibrosis
ES2799404T3 (es) 2014-07-15 2020-12-17 Yissum Research And Development Company Of The Hebrew Univ Of Jerusalem Ltd Polipéptidos de CD44 aislados y usos de los mismos
JP6706023B2 (ja) 2014-12-10 2020-06-03 ザ・スクリップス・リサーチ・インスティテュート 線維症の小分子阻害剤
AU2018251415B2 (en) 2017-04-11 2021-08-05 Mitsui Chemicals Crop & Life Solutions, Inc. Pyridone compounds and agricultural and horticultural fungicides containing the same as active ingredients
AU2020397917A1 (en) 2019-12-04 2022-06-23 The Scripps Research Institute GLP2 receptor agonists and methods of use
MX2023014771A (es) 2021-06-09 2024-03-19 Scripps Research Inst Conjugados peptidicos duales gip/glp-1 de accion prolongada y metodos de uso.

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4101664A (en) * 1975-10-06 1978-07-18 Janssen Pharmaceutica N.V. 1-(2-Ar-4-aryloxymethyl-1,3-dioxolan-2-ylmethyl)-imidazoles
US3936470A (en) * 1975-01-27 1976-02-03 Janssen Pharmaceutica N.V. 1,3-Dioxolan-2-ylmethylimidazoles
US4267179A (en) * 1978-06-23 1981-05-12 Janssen Pharmaceutica, N.V. Heterocyclic derivatives of (4-phenylpiperazin-1-yl-aryloxymethyl-1,3-dioxolan-2-yl)methyl-1H-imidazoles and 1H-1,2,4-triazoles
US4321272A (en) * 1980-08-25 1982-03-23 Syntex (U.S.A.) Inc. Derivatives of substituted N-alkylimidazoles
DE3144318A1 (de) * 1981-11-07 1983-05-19 Bayer Ag, 5090 Leverkusen 2-imidazolylmethyl-2-phenyl-1, 3-dioxolane, verfahren zu ihrer herstellung sowie ihre verwendung als fungizide
US4619931A (en) * 1983-02-28 1986-10-28 Janssen Pharmaceutica, N.V. [[4-[4-(4-phenyl-1-piperazinyl)phenoxymethyl]-1,3-dioxolan-2-yl]methyl]-1H-imidazoles and 1H-1,2,4-triazoles
CA1292472C (en) * 1985-12-03 1991-11-26 Alfonsus Guilielmus Knaeps Derivatives of ¬¬4-¬4-(4-phenyl-1-piperazinyl)- phenoxymethyl|-1,3-dioxolan-2-yl|methyl|-1h-imidazoles and 1h-1,2,4-triazoles
US4791111A (en) * 1985-12-23 1988-12-13 Janssen Pharmaceutica, N.V. [[4-[4-(4-phenyl-1-piperazinyl)phenoxymethyl]-1,3-dioxolan-2-yl]methyl]-1H-imidazoles and 1H-1,2,4-triazoles having anti-microbial properties
NZ223799A (en) * 1987-03-25 1989-12-21 Janssen Pharmaceutica Nv Azolylmethyl-dioxolanylmethoxyphenyl-piperazinyl-phenyl-triazolones and antimicrobial compositions
US4916134A (en) * 1987-03-25 1990-04-10 Janssen Pharmacuetica N.V. 4-[4-[4-[4-[[2-(2,4-difluorophenyl)-2-(1H-azolylmethyl)-1,3-dioxolan-4-yl]me]phenyl]-1-piperazinyl]phenyl]triazolones
SG48386A1 (en) * 1994-01-24 1998-04-17 Janssen Pharmaceutica Nv Watersoluble azole antifungals

Also Published As

Publication number Publication date
NZ305869A (en) 1998-08-26
HK1012186A1 (en) 1999-07-30
PL183737B1 (pl) 2002-07-31
ATE208386T1 (de) 2001-11-15
CN1181079A (zh) 1998-05-06
WO1996033193A1 (en) 1996-10-24
PL322872A1 (en) 1998-03-02
NO974690L (no) 1997-10-10
IL117980A0 (en) 1996-08-04
US6197972B1 (en) 2001-03-06
CZ291737B6 (cs) 2003-05-14
US5922718A (en) 1999-07-13
AU5399896A (en) 1996-11-07
EP0871626A1 (en) 1998-10-21
KR100413219B1 (ko) 2004-05-31
ZA963152B (en) 1997-10-20
DK0871626T3 (da) 2002-02-25
AU699313B2 (en) 1998-12-03
JP3782455B2 (ja) 2006-06-07
CN1076727C (zh) 2001-12-26
IL117980A (en) 2000-02-17
TW457240B (en) 2001-10-01
CZ328897A3 (cs) 1998-01-14
KR19980703346A (ko) 1998-10-15
DE69616825T2 (de) 2002-06-27
EP0871626B1 (en) 2001-11-07
NO312415B1 (no) 2002-05-06
HUP9801056A2 (hu) 1999-06-28
DE69616825D1 (en) 2001-12-13
HUP9801056A3 (en) 1999-09-28
JPH11503739A (ja) 1999-03-30
CA2217632A1 (en) 1996-10-24
NO974690D0 (no) 1997-10-10
PT871626E (pt) 2002-04-29

Similar Documents

Publication Publication Date Title
ES2167555T3 (es) Triazolonas como inhibidores de la sintesis de apolipoproteina-b.
NO20050016L (no) Difenylazetidinonderivater for behandling av forstyrrelser i lipid metabolismen
AR008577A1 (es) Pirazolopirimidinas, una composicion que las comprende, un procedimiento para preparar dicha composicion, un procedimiento para su preparacion,compuestos intermediarios de las mismas y un procedimiento para su preparacion
MX9204139A (es) Nuevos derivados de bencimidazolona, procedimiento para su preparacion y composicion farmaceutica que los contiene.
PE20050012A1 (es) Compuestos de benzopirano como inhibidores de la ciclooxigenasa-2
BG93979A (bg) Производни на n-(4-пиперидинил)(дихидробензофуран или дихидро-2н-бензопиран)карбоксамид, фармацевтичен състав, който ги съдържа, метод за получаване на производните и приложението им
MXPA05011710A (es) Derivados de pirimidina con actividad de crf.
ECSP034732A (es) Derivado de fenetanolamina para el tratamiento de enfermedades respiratorias
KR830006174A (ko) 기관지 항경련성 화합물 제조방법
AR041566A1 (es) Derivados de indol utiles para el tratamiento de enfermedades
MXPA04007414A (es) Indoles sustituidos como agonistas alfa-1.
MX9207335A (es) Nuevos derivados del acido fosfonosuccinico, procesos para su preparacion y composicion farmaceuticas que los contiene.
NO970349D0 (no) Forbindelser som er anvendbare som antiproliferative midler og GARFT inhibitorer
ATE103812T1 (de) Zusammensetzung zur behandlung von ischaemischen stoerungen in organen.
AR040489A1 (es) Compuestos derivados de 3-fenil-propionamido, 3-fenil-acrilamido y 3-fenil-propinamido, su uso para la elaboracion de medicamentos, un proceso para elaborar los compuestos y medicamentos que los contienen
BR0312176A (pt) Composto, composição farmaceutica, uso de um composto, método para o tratamento, método para reduzir a morbidez e a mortalidade associadas com o excesso de peso, processo para a preparação de um composto, novo intermediario e processo para a preparação de um novo intermediario
ATE243215T1 (de) Neue 2-decarboxy-2-phosphinico prostaglandin f analoge
NO20074622L (no) Metabolitter for NK-1 antagonister for brekninger
DK160297C (da) N-acyl-arylamin-derivater samt deres fremstilling og anvendelse som mikrobicider
BR0312175A (pt) Composto, composição farmacêutica, uso de um composto, método para o tratamento e método para reduzir a morbidez e a mortalidade associadas com o excesso de peso
AR004726A1 (es) Derivados 25-hidroxi-16-eno-26,27-bis homo-colecalciferol, compuestos intermediarios para su preparacion, composiciones farmaceuticas que loscontienen y uso de dichos derivados para fabricar un medicamento.
AR002264A1 (es) 6-[triazolil[3(trifluormetil)fenil]metil]-2-quinolinonas y quinolintionas, un procedimiento para su preparacion, una composicion que las comprende, unprocedimiento para su preparacion, el uso de las mismas para la preparacion de un medicamento y un intermediario.
NO924806D0 (no) Etanoladdukter av 6-sulfonylsubstituerte 3-hydroksykromaner og deres anvendelse som inhalasjonsmiddel ved sykdommer
AR003964A1 (es) Nuevos azepanos y homologos de su anillo, compuestos de partida para su preparacion, procedimiento para la elaboracion de dichos azepanos y sushomologos de anillo y composiciones farmaceuticas que los contienen.
AR032341A1 (es) N-(2-metansulfonil-etil)-n-hidroxiformamidas, su uso en la produccion de medicamentos, composiciones farmaceuticas que las contienen, procedimiento para preparar dichos compuestos e intermediarios para su preparacion